Fujirebio Diagnostics Tumor Marker Control Model 108-20
Multi-Analyte Controls, All Kinds (Assayed). 510(k) K101809, from Fujirebio Diagnostics,Inc. (Malvern, PA). Product code JJY, class 1.
As of Nov 20, 2026, K101809 is an FDA 510(k) held by Fujirebio Diagnostics,Inc., substantially equivalent on Oct 5, 2010 after 98 days, with no recalls tied to it in FDA's recall database.
- Review time: 98 days
- Recalls: 0
- Cited as a predicate by: 1 device
For In Vitro Diagnostic Use Only. Fujirebio Diagnostics Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory testing procedures for the analysis of AFP, CA15-3, CA19-9, CA125, CEA, Ferritin, HE4, PSA and Free PSA.
- Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and MinipakK082036 · Bio-Rad Laboratories · Sep 8, 2008
- Architect HE4, Architect HE4 Calibrators and Architect HE4 Controls, Models 2, 2P54, 2P54-01, 2P54-10 SP54-01,K093957 · Fujirebio Diagnostics,Inc. · Mar 18, 2010
- Fujirebio Diagnostics Tumor Marker ControlK103676 · Fujirebio Diagnostics,Inc. · Jul 19, 2011
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jun 29, 2010
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1660
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files